Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure - 09/08/11
, Takeshi Niizeki, MD a, Yo Koyama, MD a, Tatsuro Kitahara, MD a, Toshiki Sasaki, MD a, Mina Sagara b, Isao Kubota, MD aRésumé |
Background |
Pentraxin 3 (PTX3) is a novel inflammatory marker produced by endothelial cells, smooth muscle cells, and macrophages. The purpose of the present study was to examine the clinical significance of plasma PTX3 levels in patients with heart failure.
Methods |
We measured the plasma PTX3 levels in 196 patients with heart failure and 60 control subjects without heart failure by sandwich enzyme-linked immunosorbent assay. Patients were prospectively followed during a median follow-up period of 655 days with the end points of cardiac death or progressive heart failure requiring rehospitalization.
Results |
Plasma PTX3 concentrations were higher in patients with heart failure than in control subjects (P < .0001) and increased as the severity of New York Heart Association functional class advanced (P < .0001). A total of 63 cardiac events occurred during a follow-up period, and cardiac event-free rate was markedly lower in patients with high PTX3 levels than in those with normal PTX3 levels (44.7% vs 89.2%, P < .0001). The multivariate Cox proportional hazard analysis demonstrated that the plasma PTX3 level, but not the high-sensitive C-reactive protein, was the independent predictor of cardiac events (hazard ratio 1.20, 95% CI 1.03-1.40, P = .0162). Patients were divided into 4 groups based on plasma PTX3 values from first to fourth quartile. The highest fourth quartile of plasma PTX3 levels was associated with the highest risk of cardiac events (9.23-fold compared with the first quartile).
Conclusions |
The plasma PTX3 level provides important prognostic information for the risk stratification of patients with heart failure.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported in part by a grant-in-aid for Scientific Research (no. 19590804) from the Ministry of Education, Science, Sports and Culture, Tokyo, Japan; a grant-in-aid from the 21st Century Center of Excellence program of the Japan Society for the Promotion of Science, Tokyo, Japan; and grants from Takeda Science Foundation, Osaka, Japan, and Fukuda Foundation for Medical Technology, Tokyo, Japan. |
Vol 155 - N° 1
P. null - janvier 2008 Retour au numéro
Article précédent
- Recovery of normal ventricular function in patients with dilated cardiomyopathy: Predictors of an increasingly prevalent clinical event
- Philip F. Binkley, Amanda Lesinski, Jeanette Pohorence Ferguson, Patricia S. Hatton, Laura Yamokoski, Sheetal Hardikar, Glen E. Cooke, Carl V. Leier
- Cystatin C and risk of heart failure in the Physicians' Health Study (PHS)
- Luc Djoussé, Tobias Kurth, J. Michael Gaziano
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?